Skip to main content
. 2018 Aug 18;13:29–43. doi: 10.1016/j.omtn.2018.08.006

Figure 6.

Figure 6

miR-26b Protects ECs and Myocytes from Ischemic Injury

(A and B) Expression of (A) miR-26b and (B) PTEN in ECs sorted from adductor muscles and total adductor muscles 3 days after ischemia and intramuscular oligonucleotide delivery. Error bars are mean ± SEM; **p < 0.01 compared to controls (n = 5 animals per group, unpaired t test). (C) Representative images of H&E staining of ischemic adductor muscles injected with miR-26b mimic or control mimic. Scale bar, 500 μm. Lower panel: quantitative analysis of muscle necrosis extent in the ischemic adductor muscles injected with miR-26b mimic and control mimic (necrosis area was normalized to the total muscle area) is shown (n = 5 per group). Error bars are mean ± SEM; **p < 0.01 compared to control mimic (n = 5 animals per group, unpaired t test). (D) Representative images of TUNEL staining of ischemic adductor muscles injected with miR-26b mimics or control mimic. CD31, red; TUNEL staining, green; DAPI, blue. Scale bars, 30 μm. Lower panel: quantification of ECs or myocytes positive for TUNEL staining is shown. Error bars are mean ± SEM; *p < 0.05 and ***p < 0.001 compared to control (n = 5 animals per group, unpaired t test).